Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential

NCT02419378 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Alemtuzumab

Sponsor

University Hospital Muenster

Collaborators

[object Object]